MAPT and neurodegenerative disease: There is an urgent need for noninvasive, reliable fluid biomarkers to diagnose early TDP-43 pathology to improve the differential diagnosis with overlapping neurodegenerative diseases that undoubtedly exhibit an extreme variability in clinical phenotypes, as described by Virgilio et al., for tau [112].